GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Jubilant Pharmova Ltd (BOM:530019) » Definitions » Retained Earnings

Jubilant Pharmova (BOM:530019) Retained Earnings : ₹0 Mil (As of Jun. 2024)


View and export this data going back to 1995. Start your Free Trial

What is Jubilant Pharmova Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Jubilant Pharmova's retained earnings for the quarter that ended in Jun. 2024 was ₹0 Mil.

Jubilant Pharmova's quarterly retained earnings increased from Dec. 2023 (₹0 Mil) to Mar. 2024 (₹45,397 Mil) but then declined from Mar. 2024 (₹45,397 Mil) to Jun. 2024 (₹0 Mil).

Jubilant Pharmova's annual retained earnings declined from Mar. 2022 (₹46,850 Mil) to Mar. 2023 (₹45,368 Mil) but then increased from Mar. 2023 (₹45,368 Mil) to Mar. 2024 (₹45,397 Mil).


Jubilant Pharmova Retained Earnings Historical Data

The historical data trend for Jubilant Pharmova's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jubilant Pharmova Retained Earnings Chart

Jubilant Pharmova Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 38,448.17 43,177.11 46,850.17 45,368.00 45,397.00

Jubilant Pharmova Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 45,397.00 -

Jubilant Pharmova Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Jubilant Pharmova  (BOM:530019) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Jubilant Pharmova Business Description

Traded in Other Exchanges
Address
1A, Sector 16A, Noida, UP, IND, 201 301
Jubilant Pharmova Ltd is an integrated global pharmaceutical company. The company's segment includes Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research, Development and Manufacturing Organisation and Proprietary Novel Drugs. It generates maximum revenue from the Radiopharma segment. Geographically, it derives a majority of its revenue from Americas and Europe.

Jubilant Pharmova Headlines

No Headlines